BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Weisel K, Scott N, Berger S, Wang S, Brown K, Powell M, Broer M, Watts C, Tompson DJ, Burriss SW, Hawkins S, Abbott-Banner K, Tak PP. A randomised, placebo-controlled study of RIPK1 inhibitor GSK2982772 in patients with active ulcerative colitis. BMJ Open Gastroenterol 2021;8:e000680. [PMID: 34389633 DOI: 10.1136/bmjgast-2021-000680] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Tao Y, Murakami Y, Vavvas DG, Sonoda KH. Necroptosis and Neuroinflammation in Retinal Degeneration. Front Neurosci 2022;16:911430. [PMID: 35844208 DOI: 10.3389/fnins.2022.911430] [Reference Citation Analysis]
2 Horne CR, Samson AL, Murphy JM. The web of death: the expanding complexity of necroptotic signaling. Trends Cell Biol 2022:S0962-8924(22)00139-8. [PMID: 35750616 DOI: 10.1016/j.tcb.2022.05.008] [Reference Citation Analysis]
3 Tompson D, Whitaker M, Pan R, Johnson G, Fuller T, Zann V, McKenzie L, Abbott-Banner K, Hawkins S, Powell M. Development of a Once-Daily Modified-Release Formulation for the Short Half-Life RIPK1 Inhibitor GSK2982772 using DiffCORE Technology. Pharm Res 2022. [PMID: 34988780 DOI: 10.1007/s11095-021-03124-7] [Reference Citation Analysis]
4 Wang L, Zhou L, Zhou Y, Liu L, Jiang W, Zhang H, Liu H. Necroptosis in Pulmonary Diseases: A New Therapeutic Target. Front Pharmacol 2021;12:737129. [PMID: 34594225 DOI: 10.3389/fphar.2021.737129] [Cited by in F6Publishing: 1] [Reference Citation Analysis]